Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opicapone Treatment Initiation Open-Label Study

Trial Profile

Opicapone Treatment Initiation Open-Label Study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicapone (Primary) ; Levodopa/carbidopa
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OPTI-ON
  • Sponsors Neurocrine Biosciences
  • Most Recent Events

    • 27 Apr 2023 Results(n=164) assessing patient-reported outcomes (PROs) from the Opicapone Treatment presented at the 75th Annual Meeting of the American Academy of Neurology 2023
    • 23 Nov 2022 Status changed from active, no longer recruiting to completed.
    • 24 Oct 2022 According to Neurocrine Biosciences media release, the company presented data detailing the baseline characteristics of patients with Parkinson's disease at the 2022 American Neurological Association Annual Meeting (ANA2022) being held from 22nd-25th October.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top